Lipid lowering therapy (LLT) is being initiated in about one in five patients found to have elevated Lp(a) and not previously prescribed these agents, an analysis of the TriNetX Database (2021-2026) has shown.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
